BHV-1300 is a small molecule commercialized by Biohaven, with a leading Phase I program in Rheumatoid Arthritis. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of BHV-1300’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData


Data Insights Net Present Value Model: Biohaven Ltd's BHV-1300

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for BHV-1300 is expected to reach an annual total of $104 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

BHV-1300 Overview

BHV-1300 (BH 2640) is under development for the treatment of unspecified autoimmune disorders and rheumatoid arthritis. The drug candidate is administered through subcutaneous and intravenous route. It acts by targeting immunoglobulin G (IgG) and asialoglycoprotein receptor (ASGPR) and is being developed based on Molecular Degrader of Extracellular Protein (MoDE) platform.

Biohaven Overview

Biohaven formerly Biohaven Research, is biopharmaceutical company discovering, developing, and commercializing novel therapies for the treatment of neurological and neuropsychiatric diseases. Biohaven is headquartered in Tortola, British Virgin Islands.
The operating loss of the company was US$436.1 million in FY2023, compared to an operating loss of US$567.9 million in FY2022. The net loss of the company was US$408.2 million in FY2023, compared to a net loss of US$570.3 million in FY2022.

For a complete picture of BHV-1300’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.